Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer). Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).
Read the full article on WikipediaAdvanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma Clinical criteria: Treatment Phase: Initial treatment Patient must be undergoing combination treatment with PBS-subsidised durvalumab, AND Patient must have a WHO performance status of 0 or 1, AND Patient must not be suitable for transarterial chemoembolisation, AND Patient must have Child Pugh class A, AND The condition must be untreated with systemic therapy; OR Patient must have developed intolerance of a severity necessitating permanent treatment withdrawal, in the absence of disease progression to a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). Treatment criteria: Patient must not be undergoing PBS-subsidised treatment with this drug for this indication more than once per lifetime.
“Tremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells.”
Working under the parallel aged-care framework? Aged-care equivalent →